Vandetanib versus erlotinib in patients with previously treated advanced NSCLC: a randomized, double-blind phase III trial (ZEST)

被引：0
|
作者：
Natale, Ronald B. [1 ]
Thongprasert, Sumitra [2 ]
Greco, F. Anthony [3 ]
Thomas, Michael [4 ]
Tsai, Chun-Ming [5 ]
Sunpaweravong, Patrapim [6 ]
Ferry, David [7 ]
Langmuir, Peter [8 ]
Gogov, Sven [9 ]
Rowbottom, Jacqui A. [9 ]
Goss, Glenwood D. [10 ]
机构：
[1] Cedars Sinai Canc Ctr, Los Angeles, CA USA
[2] Chiang Mai Univ, Maharaj Nakorn Chiang Mai Hosp, Chiang Mai 50000, Thailand
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Univ Heidelberg, Heidelberg, Germany
[5] Taipei Vet Gen Hosp, Taipei, Taiwan
[6] Prince Songkla Univ, Songkhla, Thailand
[7] New Cross Hosp, Wolverhampton, W Midlands, England
[8] AstraZeneca, Wilmington, DE USA
[9] AstraZeneca, Macclesfield, Cheshire, England
[10] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 50 条
  • [1] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [2] Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST)
    Natale, R. B.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Langmuir, P.
    Rowbottom, J. A.
    Goss, G. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC)
    Herbst, Roy S.
    Sun, Yan
    Korfee, Soenke
    Germonpre, Paul
    Saijo, Nagahiro
    Zhou, Caichun
    Wang, Jie
    Langmuir, Peter
    Tada, Hiroomi
    Kennedy, Sarah J.
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S357 - S358
  • [4] Vandetanib plus pernetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL)
    de Boer, Richard H.
    Arrieta, Oscar
    Gottfried, Maya
    Blackhall, Fiona H.
    Raats, Johann
    Yang, Chih-Hsin
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S356 - S357
  • [5] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    Wells, Samuel A., Jr.
    Robinson, Bruce G.
    Gagel, Robert F.
    Dralle, Henning
    Fagin, James A.
    Santoro, Massimo
    Baudin, Eric
    Elisei, Rossella
    Jarzab, Barbara
    Vasselli, James R.
    Read, Jessica
    Langmuir, Peter
    Ryan, Anderson J.
    Schlumberger, Martin J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 134 - 141
  • [6] Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Mulatero, Clive
    Whorf, Robert
    Thompson, Joyce
    Barlesi, Fabrice
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1059 - 1066
  • [7] A RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF ICOTINIB VERSUS GEFITINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CHEMOTHERAPY (ICOGEN)
    Sun, Yan
    Shi, Yankai
    Zhang, Li
    Liu, Xiaoqing
    Zhou, Caicun
    Zhang, Li
    Wang, Dong
    Li, Qiang
    Zhang, Shucai
    Qin, Shukui
    Hu, Chunhong
    Zhang, Yiping
    Tan, Fenlai
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S317 - S318
  • [8] A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)
    Sun, Y.
    Shi, Y.
    Zhang, L.
    Liu, X.
    Zhou, C.
    Zhang, L.
    Wang, D.
    Li, Q.
    Zhang, S.
    Qin, S.
    Hu, C.
    Zhang, Y.
    Chen, J.
    Song, Y.
    Feng, J. F.
    Cheng, Y.
    Zhang, H.
    Wu, Y. L.
    Xu, N.
    Zhou, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] ARCHER: DACOMITINIB (D; PF-00299804) VERSUS ERLOTINIB (E) FOR ADVANCED (ADV) NSCLC; A RANDOMIZED DOUBLE-BLIND PHASE III STUDY
    Boyer, M.
    Jaenne, P. A.
    Mok, T.
    O'Byrne, K.
    Paz-Ares, L.
    Ramalingam, S. S.
    Liang, J.
    Taylor, I.
    Campbell, A.
    O'Connell, J.
    Letrent, S.
    Lee, S. -Y.
    Antic, V.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 22 - 23
  • [10] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Eberhardt, W. E. E.
    Johnson, B. E.
    Sun, Y.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Tada, H.
    Kennedy, S.
    Herbst, R. S.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 505 - 505
12345